Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CRVS Stock Forecast 2026-2027
$11.12
Current Price
$935.09M
Market Cap
Buy 7
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CRVS Price Targets
+277.7%
To High Target of $42.00
+183.3%
To Median Target of $31.50
+142.8%
To Low Target of $27.00
CRVS Price Momentum
-10.4%
1 Week Change
-28.0%
1 Month Change
+184.4%
1 Year Change
+44.4%
Year-to-Date Change
-58.7%
From 52W High of $26.95
+213.2%
From 52W Low of $3.55
📊 TOP ANALYST CALLS
Did CRVS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Corvus is one of their latest high-conviction picks.
Latest CRVS Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, CRVS has a bullish consensus with a median price target of $31.50 (ranging from $27.00 to $42.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $11.12, the median forecast implies a 183.3% upside. This outlook is supported by 7 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CRVS Analyst Ratings
7
Buy
0
Hold
0
Sell
CRVS Price Target Range
Low
$27.00
Average
$31.50
High
$42.00
Current: $11.12
Latest CRVS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CRVS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 17, 2026 | Goldman Sachs | Paul Choi | Buy | Initiates | $40.00 |
| Mar 13, 2026 | Oppenheimer | Outperform | Reiterates | $N/A | |
| Jan 22, 2026 | Jefferies | Buy | Maintains | $N/A | |
| Jan 21, 2026 | Oppenheimer | Outperform | Maintains | $N/A | |
| Jan 21, 2026 | Barclays | Overweight | Maintains | $N/A | |
| Jan 20, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 13, 2025 | Barclays | Overweight | Initiates | $N/A | |
| May 20, 2025 | Mizuho | Outperform | Maintains | $N/A | |
| May 9, 2025 | Oppenheimer | Outperform | Reiterates | $N/A | |
| Mar 26, 2025 | Oppenheimer | Outperform | Maintains | $N/A | |
| Mar 26, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 14, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 2, 2025 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Nov 13, 2024 | Oppenheimer | Outperform | Reiterates | $N/A | |
| Sep 16, 2024 | Ladenburg Thalmann | Buy | Maintains | $N/A | |
| May 7, 2024 | Oppenheimer | Outperform | Maintains | $N/A | |
| Apr 1, 2024 | Cantor Fitzgerald | Overweight | Reiterates | $N/A | |
| Mar 27, 2024 | Mizuho | Neutral | Maintains | $N/A | |
| Mar 20, 2024 | Oppenheimer | Outperform | Maintains | $N/A | |
| Sep 7, 2023 | Cantor Fitzgerald | Overweight | Reiterates | $N/A |
Corvus Pharmaceuticals Inc. (CRVS) Competitors
The following stocks are similar to Corvus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Corvus Pharmaceuticals Inc. (CRVS) Financial Data
Valuation Metrics
Market Cap
$935.09M
Enterprise Value
$749.66M
P/E Ratio
N/A
PEG Ratio
-12.4x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+25.3%
Current Ratio
19.8x
Debt/Equity
0.3x
ROE
-30.5%
ROA
-19.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Corvus Pharmaceuticals Inc. (CRVS) Business Model
About Corvus Pharmaceuticals Inc.
What They Do
Develops immune-modulating therapies for cancer treatment.
Business Model
The company operates as a clinical-stage biopharmaceutical firm, generating revenue primarily through the development and commercialization of investigational therapies for cancer and immune-mediated diseases. It focuses on ITK inhibition and has a pipeline of product candidates that include partnerships and collaborations to enhance its research and development efforts.
Additional Information
Founded in 2014 and based in South San Francisco, Corvus Pharmaceuticals is advancing several immune modulators and participating in clinical trials to address various conditions. Its strategic collaborations, such as with Angel Pharmaceuticals, aim to expand its market reach, particularly in regions like greater China.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
37
CEO
Dr. Richard A. Miller M.D.
Country
United States
IPO Year
2016
Website
www.corvuspharma.comCorvus Pharmaceuticals Inc. (CRVS) Latest News & Analysis
Latest News
Quick Summary
Corvus Pharmaceuticals (NASDAQ: CRVS) will hold one-on-one investor meetings and present at the Jefferies Global Healthcare Conference on June 3 and Goldman Sachs Conference on June 8, 2026.
Why It Matters
Corvus Pharmaceuticals' upcoming investor meetings at major healthcare conferences could signal potential partnerships or funding opportunities, impacting stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Corvus Pharmaceuticals is rated a Sell due to valuation exceeding fundamentals. Phase 1 data for Soquelitinib shows promise but raises safety and efficacy concerns. Fair value is $10.07/share, indicating 16% downside.
Why It Matters
Corvus Pharmaceuticals faces potential downside due to overvaluation against fundamentals, uncertain drug efficacy, and future cash needs that may lead to dilution, impacting shareholder value.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Corvus Pharmaceuticals, Inc. (CRVS) held a shareholder/analyst call, discussing company updates and financial performance. Further details can be found in the transcript.
Why It Matters
The shareholder/analyst call provides insights into Corvus Pharmaceuticals' performance, strategy, and future prospects, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
New data on soquelitinib shows potential to enhance Treg cells and affect inflammatory pathways, suggesting it may lead to drug-free remissions. The company will discuss findings in an investor meeting today.
Why It Matters
Positive data on soquelitinib's efficacy in enhancing immune response and potential for drug-free remissions could boost investor confidence and drive stock performance in the biopharma sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results
30 days ago
Quick Summary
Corvus Pharmaceuticals reported positive Phase 1 data for soquelitinib in atopic dermatitis and is initiating a Phase 2 trial. An investor meeting is scheduled for May 14, 2026.
Why It Matters
Positive Phase 1 data and a progressing Phase 2 trial for soquelitinib enhance Corvus Pharmaceuticals' growth potential, signaling promising advancements in atopic dermatitis treatment that could boost stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Corvus Pharmaceuticals will present Phase 1 trial data for soquelitinib at the SID Annual Meeting on May 13-16, 2026, with an investor meeting on May 14 and Q1 2026 results on May 7.
Why It Matters
The upcoming presentations on soquelitinib’s Phase 1 trial results and the investor meeting may influence market perceptions of Corvus Pharmaceuticals' potential, impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CRVS Stock
What is Corvus Pharmaceuticals Inc.'s (CRVS) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Corvus Pharmaceuticals Inc. (CRVS) has a median price target of $31.50. The highest price target is $42.00 and the lowest is $27.00.
Is CRVS stock a good investment in 2026?
According to current analyst ratings, CRVS has 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $11.12. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CRVS stock?
Wall Street analysts predict CRVS stock could reach $31.50 in the next 12 months. This represents a 183.3% increase from the current price of $11.12. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Corvus Pharmaceuticals Inc.'s business model?
The company operates as a clinical-stage biopharmaceutical firm, generating revenue primarily through the development and commercialization of investigational therapies for cancer and immune-mediated diseases. It focuses on ITK inhibition and has a pipeline of product candidates that include partnerships and collaborations to enhance its research and development efforts.
What is the highest forecasted price for CRVS Corvus Pharmaceuticals Inc.?
The highest price target for CRVS is $42.00 from at , which represents a 277.7% increase from the current price of $11.12.
What is the lowest forecasted price for CRVS Corvus Pharmaceuticals Inc.?
The lowest price target for CRVS is $27.00 from at , which represents a 142.8% increase from the current price of $11.12.
What is the overall CRVS consensus from analysts for Corvus Pharmaceuticals Inc.?
The overall analyst consensus for CRVS is bullish. Out of 2 Wall Street analysts, 7 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $31.50.
How accurate are CRVS stock price projections?
Stock price projections, including those for Corvus Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 6, 2026 5:33 PM UTC